ReviewGut pathogens2026
Modulatory role of Akkermansia muciniphila in cancer pathophysiology: a systematic review and meta-analysis of preclinical studies.
Review in Gut pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Dual Role of the Gut Microbiota in Cancer Chemoresistance.MicrobiologyOpen · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Akkermansia muciniphila (A. muciniphila), a health-promoting bacterium in the human gut, is recognized for its role in improving immune function and metabolic health. Recent studies have uncovered its potential use as a therapeutic intervention for cancer treatment. This meta-analysis examines the impact of A. muciniphila, its extracellular vesicles (EVs), and Amuc protein on cancer outcomes in preclinical cancer models. Sixteen studies were included in the analysis through searches of relevant databases as of July 2025. Data on tumor number, volume, weight, and immune responses were extracted and analyzed. A. muciniphila and its derivatives significantly reduced tumor metrics across various cancers, including intestinal, colorectal, prostate, lung, gastric, hepatocellular, and ovarian. The intervention elevated interferon-gamma (IFNγ), CD8⁺ T cells, TNFα, and reduced IL-10 in the tumor microenvironment. Reduced spleen weight and systemic IL-6 levels indicated both local and systemic modulation of inflammation. Dose-specific effects included more substantial reductions in tumor number, size, and spleen weight at low doses (≤ 10⁸ CFU), as well as decreased tumor cell proliferation at high doses (≥ 10⁹ CFU). A. muciniphila and its derivatives exhibit significant potential in reducing cancer metrics. Their effects are mediated by regulating tumor growth, modulating both tumor microenvironment and systemic inflammatory pathways, enhancing immune regulation, and affecting gut microbiota composition. These results suggest that A. muciniphila may be a promising next-generation adjunct therapy for cancer, particularly in its non-live forms. Further exploration of the role of A. muciniphila's outer membrane proteins and metabolites through comprehensive clinical studies could unlock new therapeutic opportunities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.